Lead sponsor
Hoffmann-La Roche
23 Alzheimer’s disease and related dementias trials led. Source: ClinicalTrials.gov, as of July 21, 2026.
23
Trials led
6
Ongoing
11,604
Total enrollment
1,083
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 1
4
Phase 1/2
1
Phase 2
5
Phase 3
13
Trials by status
Not yet recruiting
1
Recruiting
3
Active, not recruiting
2
Completed
8
Terminated
9
Trials led
TrialEligibility highlightPhaseStatusEnrollment
A Study to Evaluate the Safety, Tolerability, and Efficacy of Long-Term Gantenerumab Administration in Participants With Alzheimer's Disease (AD)Study partner/caregiver requiredPh 3Terminated1,382
Efficacy and Safety Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)prodromal ADPh 3Terminated1,053
Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)prodromal ADPh 3Terminated975
A Study of Gantenerumab in Participants With Mild Alzheimer DiseaseAmyloid biomarker required (CSF)Ph 3Completed389
A Study of RO5313534 as Add-on to Donepezil Treatment in Patients With Mild to Moderate Alzheimer's DiseaseAlzheimer's diseasePh 2Completed389
A Study to Evaluate the Safety and Biomarker Effects of RO7269162 in Participants at Risk for or at the Prodromal Stage of Alzheimer's Disease (AD)MCI due to ADPh 2Active, not recruiting256
Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's DiseaseMCI due to AD / prodromal AD / mild-to-moderate AD / moderate AD dementiaPh 1/2Active, not recruiting241
A Study to Evaluate the Pharmacodynamic (PD) Effects of Once Weekly Administration of Gantenerumab in Participants With Early Alzheimer's Disease (AD)prodromal ADPh 2Terminated192
A Study to Evaluate the Safety and Tolerability of Long-term Administration of Gantenerumab in Participants With Alzheimer's Disease (AD)-Ph 3Terminated116
A Multiple Ascending Dose Study of R1450 in Patients With Alzheimer Disease.Alzheimer's diseasePh 1Completed60
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants With Early Symptomatic Alzheimer's Disease (eAD)MCI due to ADPh 1Recruiting50
A Single Ascending Dose Study to Investigate the Safety, Tolerability, Immunogenicity and Pharmacokinetics of Intravenously Administered RO7126209 in Healthy ParticipantsAge 18-40Ph 1Completed36
A Study of RO4602522 in Patients With Alzheimer Disease and in Healthy VolunteersAlzheimer's diseasePh 1Completed17